[A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome].
A patient with carcinoid syndrome was treated with the somatostatin analogue (SMS 201-995). The drug significantly improved the symptoms of the patient, flushing and diarrhea, and reduced urinary excretion of 5-hydroxyindole acetic acid. However, hepatic metastases remained unchanged. Clinical or biochemical adverse effects were not present during the treatment period.
Del Val
A
A
Servicio de Medicina Digestiva, Hospital La Fe, Valencia.
Ponce
J
J
Talens
A
A
Martí-Bonmati
L
L
Garrigues
V
V
Berenguer
J
J
D000328:Adult; D004341:Drug Evaluation; D004361:Drug Tolerance; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction
D015282:Octreotide
Respuesta favorable al análogo de la somatostatina SMS 201-995 en un paciente con síndrome carcinoide.